Home drugs Zevalin (Ibritumomab Tiuxetan)

Zevalin (Ibritumomab Tiuxetan)

This page contains brief information about ibritumomab tiuxetan and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Ibritumomab tiuxetan is approved to treat:

  • B-cell non-Hodgkin lymphoma. It is used in patients who have been treated with chemotherapy or with rituximab and have not gotten better or have had a relapse. Ibritumomab tiuxetan is combined with a radioactive substance and given with rituximab, as a type of radioimmunotherapy.

Ibritumomab tiuxetan is also being studied in the treatment of other types of cancer.

More About Ibritumomab Tiuxetan

Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.

MedlinePlus Information on Ibritumomab Tiuxetan – A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.